INVESTIGADORES
DI GENARO Maria Silvia
artículos
Título:
Attenuated Yersinia enterocolitica Mutant Strains Exhibit Differential
Autor/es:
MARÍA S. DI GENARO; MARC WAIDMANN; UWE KRAMER; NICLAS HITZIGER; ERWIN BOHN; INGO B. AUTENRIETH1
Revista:
INFECTION AND IMMUNITY
Editorial:
AMER SOC MICROBIOLOGY
Referencias:
Lugar: Washington; Año: 2003 vol. 71 p. 1804 - 1812
ISSN:
0019-9567
Resumen:
Yersinia enterocolitica mutant strains, including mutants deficient in the chaperone SycH resulting in a functional deficiency in tyrosine phosphatase (YopH), Mn-cofactored superoxide dismutase (SodA), iron-repressive protein 1 (IRP-1), and Yersinia adhesin A (YadA), were demonstrated to be highly attenuated in wildtype C57BL/6 mice. TNFRp55/, IL-12p40/, and IL-18/ mutant mice, in which the Yersinia wild-type strain causes severe systemic infections, were used to investigate whether these Yersinia mutant strains would be attenuated in immunodeficient hosts. A plasmid-cured Yersinia mutant strain was unable to colonize any of the mutant mice tested. A SycH-deficient mutant strain colonized intestinal tissues of these mice but wasattenuated for systemic infection in all of the mutant mice. Both YadA- and Irp-1-deficient Yersinia mutants were still attenuated in IL-12/ and IL-18/ mice but were pathogenic in TNFRp55/ mice. By contrast, a Yersinia sodA mutant was highly pathogenic for TNFRp55/ and IL-12p40/ mice while interleukin-18 (IL-18) was dispensable. This finding demonstrates that certain virulence factors enable yersiniae to compete with distinct cytokine-dependent host defense mechanisms. Moreover, while gamma interferon mRNA expression did not reflect protective host responses in cytokine-deficient mice, IL-10 expression coincided with a heavy splenic bacterial load and was associated with progressive infection courses. We can thus segregate minor (SodA), intermediate (YadA and IRP-1), and major (YopH) virulence factors of Y. enterocolitica. Finally, we demonstrate that, even in immunocompromised hosts, Yersinia sycH and, with some restrictions, irp-1 mutants may be suitable for use as live carrier vaccines.